Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: immunoglobulin

  • Rh Sensitization Following Induced Abortion

    In this multicenter, observational, prospective cohort study, flow cytometry was used to detect circulating fetal red blood cells (fRBCs) in maternal blood among 506 participants before and after induced abortion up to 12 weeks’ gestation. Only three participants had elevated fRBCs at baseline, and only one of these had elevated fRBC counts following the abortion, which indicates that first trimester abortion is not a risk factor for Rh sensitization.

  • Subcutaneous IVIG for Treatment of Myasthenia Gravis

    A Phase II trial comparing subcutaneous (SC) administration of pooled immunoglobulin to intravenous (IV) administration of immunoglobulin in 23 patients with seropositive myasthenia gravis demonstrated a stable course after transition from IV to SC.

  • What Is the Right Dose of Immunoglobulin to Treat CIDP?

    In this comparative trial of different doses of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy, higher doses appeared to result in a higher percentage of patients who improved. However, there was no control group and there were many confounding issues that make it difficult to reach a definitive conclusion around optimal dosing.

  • Genetic Biomarkers of Immunoglobulin Response in Patients with CIDP

    Nearly 25% of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) have a poor response to intravenous immunoglobulin treatment. Variations in the PRF1 and FCGR2B genes in CIDP patients offer insights into the heterogenous treatment response.

  • IqYmune for CIDP

    IqYmune is a highly purified 10% concentration of human immunoglobulin obtained from healthy volunteers. It appears to have similar efficacy in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as conventional intravenous immunoglobulin, with 76% of the study patients showing a significant improvement in a standardized disability score.